Rahul Banerjee: I Have Immense Faith in Oncologists’ Abilities to De-Escalate Bela-Maf
Rahul Banerjee, Assistant Professor at Fred Hutchinson Cancer Center at the University of Washington, shared a post on X by Al Garfall, Oncologist at Penn Medicine, adding:
“Very well stated – I have immense faith in oncologists’ abilities to de-escalate bela-maf as compared to the USPI… we do the same with bsAbs all the time to mitigate even more serious side effects!”
Quoting Al Garfall’s comment on Joshua Richter’s, Associate Professor of Medicine, Hematology, and Medical Oncology Center of Excellence for Multiple Myeloma at The Tisch Cancer Institute, post:
“I likewise don’t discount how onerous these side effects can be, but Bela is less dangerous than other approved therapies with serious life-threatening toxicity like CAR T and bispecifics, which we are trusted to manage and offer to patients with informed consent.”
Quoting Joshua Richter’s post:
“2 negative odac votes for blenrep. I missed the discussion, but this drug has a role in myeloma. Hoping the FDA still approves it.”
More posts featuring Rahul Banerjee.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023